تخطَّ إلى المحتوى
دليل الأدوية المصري
تابع آخر تحديثات الأسعار على واتساب

سعر سوميجران 6مجم/0.5مل سرنجات معبأة 2026

Sumigran 6 mg/0.5 ml

معلومات الدواء

التفاصيل الكاملة
عن الدواءAbout the medicine

Sumatriptan 6 mg injection (triptan) listed in Egyptian price directories for acute migraine.

Sumatriptan 6 mg injection (triptan) listed in Egyptian price directories for acute migraine.

دواعي الاستعمالUses
  • Acute treatment of migraine with or without aura in adultsالفئة: AdultsDailyMed (U.S. National Library of Medicine)
  • Acute treatment of cluster headache in adultsالفئة: AdultsDailyMed (U.S. National Library of Medicine)
  • Acute treatment of migraine with or without aura in adultsPopulation: AdultsDailyMed (U.S. National Library of Medicine)
  • Acute treatment of cluster headache in adultsPopulation: AdultsDailyMed (U.S. National Library of Medicine)
الآثار الجانبيةSide effects
  • Adverse reactions in placebo-controlled trials include sensations such as tingling, warmth/heat, pressure or tightness (including chest), dizziness and fatigue; injection-site reactions occur with the injection.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Adverse reactions in placebo-controlled trials include sensations such as tingling, warmth/heat, pressure or tightness (including chest), dizziness and fatigue; injection-site reactions occur with the injection.International label, same formulation · DailyMed (U.S. National Library of Medicine)
موانع الاستعمالContraindications
  • Ischemic coronary artery disease or coronary artery vasospasm, including Prinzmetal angina.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • History of stroke or transient ischemic attack, or hemiplegic or basilar migraine.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
عرض الكل (9)
  • Ischemic coronary artery disease or coronary artery vasospasm, including Prinzmetal angina.International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders.International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • History of stroke or transient ischemic attack, or hemiplegic or basilar migraine.International label, same formulation · DailyMed (U.S. National Library of Medicine)
Show all (9)
تحذيرات واحتياطاتWarnings & precautions
  • Serious cardiac events (myocardial ischemia/infarction, Prinzmetal angina, arrhythmias) can occur; evaluate patients with cardiovascular risk factors before use.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Serotonin syndrome may occur, particularly with SSRIs, SNRIs, TCAs or MAO inhibitors.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Significant blood pressure elevation, including hypertensive crisis, has been reported.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
عرض الكل (4)
  • Serious cardiac events (myocardial ischemia/infarction, Prinzmetal angina, arrhythmias) can occur; evaluate patients with cardiovascular risk factors before use.International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • Serotonin syndrome may occur, particularly with SSRIs, SNRIs, TCAs or MAO inhibitors.International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • Significant blood pressure elevation, including hypertensive crisis, has been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)
Show all (4)
التداخلات الدوائيةDrug interactions
  • Ergot-containing drugsAdditive vasospastic effects; use within 24 hours is contraindicated.DailyMed (U.S. National Library of Medicine)
  • MAO-A inhibitorsIncrease systemic exposure to sumatriptan; concurrent use or use within 2 weeks is contraindicated.DailyMed (U.S. National Library of Medicine)
  • Other 5-HT1 agonists (triptans)Additive vasospastic effects; use within 24 hours of each other is contraindicated.DailyMed (U.S. National Library of Medicine)
عرض الكل (4)
  • Ergot-containing drugsAdditive vasospastic effects; use within 24 hours is contraindicated.DailyMed (U.S. National Library of Medicine)
  • MAO-A inhibitorsIncrease systemic exposure to sumatriptan; concurrent use or use within 2 weeks is contraindicated.DailyMed (U.S. National Library of Medicine)
  • Other 5-HT1 agonists (triptans)Additive vasospastic effects; use within 24 hours of each other is contraindicated.DailyMed (U.S. National Library of Medicine)
Show all (4)
الحمل والرضاعةPregnancy & breastfeeding
  • Pregnancy registry and epidemiological data have not detected an increased frequency or consistent pattern of birth defects; animal studies showed embryolethality and fetal abnormalities.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Sumatriptan is excreted in human milk after subcutaneous administration; infant exposure can be minimised by avoiding breastfeeding for 12 hours after treatment.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Pregnancy registry and epidemiological data have not detected an increased frequency or consistent pattern of birth defects; animal studies showed embryolethality and fetal abnormalities.International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • Sumatriptan is excreted in human milk after subcutaneous administration; infant exposure can be minimised by avoiding breastfeeding for 12 hours after treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)
كيف يعمل الدواءHow it works
  • Agonist at 5-HT1B/1D receptors on intracranial blood vessels and trigeminal sensory nerves, causing cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release (US label).
  • Sumatriptan: Agonist at 5-HT1B/1D receptors on intracranial blood vessels and trigeminal sensory nerves, causing cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release (US label).

المعرّفات

مراجع علمية للمادة الفعالة

المصادر

تعليقات

لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.

أضف تعليقًا

0/60

لا يُنشر أبدًا؛ للتواصل فقط إن لزم.

0/1000

من 20 إلى 1000 حرف. بدون روابط.

التعليقات للمعلومات العامة ولا تُعد نصيحة طبية. لا تذكر بيانات شخصية.